Xilio Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 24.61 million compared to USD 23.18 million a year ago. Basic loss per share from continuing operations was USD 0.9 compared to USD 31.48 a year ago.
For the six months, net loss was USD 45.97 million compared to USD 39.85 million a year ago. Basic loss per share from continuing operations was USD 1.68 compared to USD 55.16 a year ago.